Liryc aims to transfer the knowledge gained to develop innovative technologies for the diagnosis or treatment of heart rhythm disorders.
Commercialising research results means supporting a discovery, technology or skill to turn it into a new product on the market.
Through its unique infrastructure, Liryc promotes relations between research teams, clinical teams stakeholders in the business community: medical device, drug or imaging equipment manufacturers, major groups, start-ups, actors in technology transfer, etc. This close collaboration is the breeding ground for the development of innovative projects to invent diagnostic tools, state-of-the-art medical devices and therapies of the future
Through its commercialisation policy, Liryc is surrounding itself with industrial partners and financiers with the best tools to help optimise its inventions, hence accelerating their availability for the benefit of patients. Indeed, developing innovation is a long and expensive process, which requires additional resources to those available at the Institute.